RenovoRx Inc (RNXT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.72 (-0.58%), Market cap $0.04B, 52-week low–high $0.73 ~ $1.42.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Financial statements, price targets, institutional (13F) holdings and related news for RenovoRx Inc are updated in real time on BlackAll Trade.
RenovoRx Inc trades at $1.72 (-0.58%). Real-time quotes and charts are available on BlackAll Trade.
RenovoRx Inc has a market cap of about $0.04B.
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead prod